The FDA's new Quality Management System Regulation is live. Most manufacturers are not ready. This guide shows you exactly what to do next — and how Qualera can accelerate your transition.
No credit card required. Instant access upon form submission.
QMSR doesn't introduce entirely new problems. It intensifies the ones you already have. Manual systems that were barely keeping up with the old QSR are now facing a standard of rigor they cannot sustain.
An FDA finding at one of your suppliers automatically flags your OEM for the same issue, compounding your audit risk across your entire supply chain.
Manual quality systems cannot sustain the documentation rigor, supplier oversight, and risk management requirements of the new regulation.
The FDA published its new inspection manual just one business day before QMSR went live. If you haven't been preparing for years, you're already behind.
The most dangerous risks aren't the ones you find in your own facility. They're the ones you don't see coming from your supply chain. An FDA audit finding at one of your contract manufacturers doesn't just stay there — it "rolls uphill," automatically flagging your OEM for the same issue and compounding your audit exposure with every supplier in your network.
An FDA investigator issues a 483 to your contract manufacturer for an issue related to your product. The finding is logged in the FDA's system and linked directly to your OEM.
Trigger: A single audit at one of your hundreds of suppliers.The finding rolls uphill. A note is added to your OEM's FDA audit file. Your next inspection is now pre-disposed to scrutinize that same area from the OEM perspective, putting you on the defensive before the investigator walks in the door.
Impact: Increased scrutiny and a higher likelihood of an OEM-level 483.For an OEM with 800 suppliers, approximately 40 of which are audited by the FDA annually, the risk is exponential. Each supplier finding is another strike against you, creating a compounding risk profile that is impossible to manage with manual systems.
Result: A massive, hidden, and unmanaged compliance risk across your entire supply chain.QMSR's new supplier control requirements — including documented evaluation, ongoing monitoring, and re-evaluation — mean the FDA now expects you to have active visibility into your supply chain. If you cannot demonstrate that visibility, the Rollsuphill Effect becomes a Warning Letter.
Cost: Millions in remediation + reputational damage if left unmanaged.This guide is written by former OEM executives who have lived through FDA inspections, Warning Letters, and quality system overhauls. It gives you the actionable steps you need to move from understanding the changes to implementing them.
A clear, side-by-side breakdown of what has changed and what the practical impact is for your quality system.
Understand the true cost of non-compliance at every stage of the escalation path, from Form 483 to Consent Decree.
Specific guidance on CP 7382.850 — the new inspection manual — so you know exactly what an investigator will look for.
Understand how QMSR alignment with ISO 13485:2016 impacts MDSAP participation and international commercialization.
A printable checklist to track your progress through all 10 steps and ensure nothing is missed.
A practical framework for identifying and mitigating the compounding risks of the Rollsuphill Effect across your supply chain.
The 10-step framework in this guide is actionable and practical. But manual execution cannot scale to meet the cross-functional rigor of CP 7382.850. That's where Qualera comes in.
Qualera is the premier AI-based QMS and audit-building tool that automates the most critical steps of your QMSR transition:
Result: Reduce audit preparation time by up to 50% while achieving the comprehensive, cross-functional compliance the FDA now demands.
Traditional audit tools sample 5–15% of your documentation. Qualera analyzes 100%. Traditional systems check boxes. Qualera reasons across your entire QMS, identifying the cross-functional connections that escalate to Warning Letters.
Monica Burt & Associates provides both the strategic guidance (the "what") and the technological tools (the "how") to achieve QMSR compliance seamlessly.
Consulting: Expert gap assessments, remediation strategy, and ongoing support from former OEM executives.
SaaS: Qualera automates the heavy lifting, giving you speed, scale, and confidence.
If you are a large OEM, you qualify for a complimentary QMSR Transition Executive Briefing. Our team will walk through your specific compliance gaps, regulatory exposure, and a customized roadmap for Qualera integration.
Complete the form to receive your guide instantly. No spam, no sales calls unless you request them — just the information you need to protect your business.
Monica Burt & Associates is a team of seasoned MedTech professionals with decades of experience in corporate OEM quality and regulatory affairs. We are not generalist consultants; we are former industry insiders who have built, managed, and defended quality systems at the companies your team works with every day.
We didn't just survive audits — we built Qualera to fix the systemic issues we experienced. We partner with innovators to navigate complex regulatory landscapes, ensure quality excellence, and accelerate market success — with integrity, precision, and unwavering commitment.
Our Promise: We stick with it until it's done—and done right—at our cost.
Don't wait for a Form 483 to find out you're not ready.